Bioadvise ApS: Financial statements 2022
CVR: 39920034
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Bioadvise ApS (CVR 39920034) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -154,075 and a net result of DKK -175,811 compared with DKK 53,189 the year before. Equity in the 2022 report amounted to DKK 204,910. The solvency ratio was 88%.
- Gross Profit
- DKK -154,075
- Profit/Loss
- DKK -175,811
- Equity
- DKK 204,910
- Total Assets
- DKK 232,884
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -154 t. | -176 t. | 205 t. | 0 |
| 2021 | - | 122 t. | 53 t. | 381 t. | 0 |
| 2020 | - | 448 t. | 91 t. | 289 t. | 1 |
| 2019 | - | 377 t. | 77 t. | 198 t. | 1 |
Official annual report
Keep an eye on Bioadvise ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
Bioadvise ApS has published its annual report for 2021. Gross profit came to DKK 122,164, and the net result was DKK 53,189.
About Bioadvise ApS
Bioadvise ApS was a Danish company of the type Anpartsselskab based in Kongens Lyngby, founded in 2018. The company has been dissolved on 21 September 2026. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named Bioadvise IVS. The company has 1 employee (2020). In 2025, the company reported a gross profit of DKK 0 and a net result of DKK 0 compared with DKK -210,600 the year before. Equity in the 2025 report amounted to DKK -34,634.